ANI Pharmaceuticals
ANIP
284 hedge funds and large institutions have $1.67B invested in ANI Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 114 increasing their positions, 77 reducing their positions, and 32 closing their positions.
53% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 32
48% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 77
6% more funds holding
Funds holding: 269 → 284 (+15)
0.16% more ownership
Funds ownership: 94.1% → 94.26% (+0.16%)
11% less capital invested
Capital invested by funds: $1.87B → $1.67B (-$198M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less call options, than puts
Call options by funds: $11.5M | Put options by funds: $25.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$41.1M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$14.7M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$14.2M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$12.6M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$48.5M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$38M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$31.5M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$26.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.1M |
ANIP Hedge Fund Activity: Q4 2025 in Review
284 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2025, worth a combined $1.67B — down 11% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ANIP positions and 32 closed out — a net gain of 17 holders — while 114 added to existing stakes and 77 trimmed.
The largest buyer was Millennium Management, adding an estimated $41.1M. The largest seller was Citadel Advisors, cutting an estimated $48.5M.
- 284 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2025, up from 269 in Q3 2025.
- Funds reported $1.67B of ANI Pharmaceuticals stock for Q4 2025, down 11% quarter-over-quarter.
- 49 funds opened new ANI Pharmaceuticals positions in Q4 2025 and 32 closed out, a net change of +17 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2025 was Millennium Management, an estimated $41.1M added.
- The largest ANI Pharmaceuticals seller in Q4 2025 was Citadel Advisors, an estimated $48.5M sold.
Based on aggregated 13F filings for Q4 2025.